Thursday, November 12, 2026

AI video generation costs drop from hundreds to single digits per minute as four platforms dominate $847M market

Per-minute AI video generation costs fell from several hundred dollars in 2024 to single-digit dollars in 2026, driving enterprise adoption and market consolidation. The global AI video generation sector is projected to reach $847 million in 2026 revenue, with Google's Veo 3.1 and OpenAI leading four dominant platforms. Production teams that once required 50-100 people now operate with fewer than 10.

AI video generation costs drop from hundreds to single digits per minute as four platforms dominate $847M market
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

AI video generation costs collapsed from several hundred dollars per minute in 2024 to single-digit dollars by early 2026, according to industry analysis tracking the sector's shift from research to commercial deployment.

The global AI video generation market is projected to generate $847 million in revenue for 2026. Four platforms now dominate the competitive landscape: Google's Veo 3.1, OpenAI, and two other principal providers consolidated market share as cost compression accelerated enterprise adoption.

Cuty AI announced a unified image and video creation platform on February 9, 2026, joining the commercial transition. The platform launch reflects broader industry movement away from academic research toward industrial-scale production systems.

Production capabilities changed dramatically. Video creation that required teams of 50-100 people in 2024 now operates with fewer than 10 staff members using AI platforms. The workforce reduction stems from automated processes handling tasks that previously demanded specialized human labor across rendering, editing, and post-production.

Enterprise adoption rates in Q1-Q2 2026 will test whether the cost decline and platform consolidation drive sustained commercial growth. Market share distribution among the four leading providers and continued pricing trends will indicate whether the sector stabilizes or faces additional disruption.

The technology graduated from research labs to production environments starting January 1, 2026, marking the formal transition to industrial application. Previous experimental deployments gave way to commercial contracts as platforms demonstrated reliability at scale.

Team size reductions at video production companies signal structural change in the industry. Studios adapted workflows around AI capabilities, eliminating mid-level production roles while retaining creative direction and technical oversight positions.

The 98% cost reduction from 2024 to 2026 matches historical patterns in computational technology, where hardware improvements and algorithmic efficiency combine to compress prices. Per-minute generation costs approaching single digits make AI video economically viable for marketing, entertainment, and enterprise communication applications that couldn't justify earlier pricing.

Market consolidation around four platforms suggests network effects and capital requirements created barriers to entry. Smaller providers face challenges competing on price, capability, and integration partnerships as dominant platforms establish enterprise relationships.

In this story

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com